Back

Vutrisiran-mediated knockdown of transthyretin in patients with transthyretin amyloidosis

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Transthyretin amyloidosis: long-term outcomes and emerging therapies Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Vincent Algalarrondo

Hospital Bichat-Claude Bernard, Paris (France)

6 More presentations in this session

Presentation thumbnail
CMR outcomes following one-time in vivo CRISPR editing with nexiguran ziclumeran in patients with ATTR-CM: phase 1 results
Doctor Y. Razvi (London, GB)
Abstract Slides Video
Presentation thumbnail
Long term treatment with tafamidis in ATTR-CM: 7.5 year outcomes from the phase 3 open label long-term extension study
Doctor T. Damy (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
A trial emulation study comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy using calibration and indirect treatment comparison methods: the ReplicATTR Study
Doctor P. Zwetsloot (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Influence of disease modifying therapy on the effectiveness of vutrisiran in transthyretin cardiac amyloidosis
Doctor A. Abovich (Boston, US)
Abstract Slides Video
Presentation thumbnail
Safety profile of acoramidis in cardiac amyloidosis: insights from post-marketing pharmacovigilance data
Mrs J. Gu (Erie, US)
Abstract Slides Video

Access the full session

Session thumbnail
Transthyretin amyloidosis: long-term outcomes and emerging therapies
Video

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy in HELIOS-B who had progressed on tafamidis
thumbnail
Congress Session
Transthyretin amyloidosis: long-term outcomes and emerging therapies
thumbnail
Congress Presentation
HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources